Multimodal Ultrasound and Focal Liver Lesions (FLLs)

Last updated: August 3, 2023
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Liver Cancer

Digestive System Neoplasms

Primary Biliary Cholangitis

Treatment

Ultrasound

Clinical Study ID

NCT05977764
2824
  • Ages > 18
  • All Genders

Study Summary

Background and aim: FLLs are common findings in abdominal ultrasound and differential diagnosis between benign and malignant lesions is often challenging, especially in patients with chronic liver diseases. The diagnostic role of CEUS has already been defined by international guidelines when lesions show a typical pattern for hepatocellular carcinoma whereas in case of non-typical contrast enhanced patterns radiologic imaging or liver biopsy are still needed. However, these techniques are more invasive and expensive than ultrasound. Therefore, the aim of this study is to identify D-CEUS and SWE quantitative parameters useful for characterizing FLLs.

Study design: Prospective, observational, single-center study Methods: 50 consecutive adult patients with focal liver lesions detectable with B-mode ultrasound will be enrolled in the Unit of Internal Medicine and Gastroenterology of the Policlinico Gemelli. Exclusion criteria will be liver failure, hearth failure, previous locoregional or systemic treatments for FLLs (e.g. ablation, chemoembolization, alcoholization, chemotherapy), known allergy to ultrasound contrast agents. After obtaining informed consent and identifying the target lesion in B-mode ultrasound, patients will undergo CEUS and SWE and, subsequently, to computed tomography/magnetic resonance/biopsy according to international guidelines and current clinical practice. The average, maximum, minimum and standard deviation value of lesion elasticity in KPa will be calculated using SWE. Three consecutive SWE acquisitions will be performed both for the lesion and for the liver parenchyma and the average value of the three measurements will be considered. The CEUS will allow the construction of signal intensity curves as a function of time in a specific area of interest drawn manually. From these curves a series of quantitative parameters related to the flow and volume of blood will be extrapolated and in particular: peak intensity, PI (in Arbitrary Units, AU); time to peak, TP ( in seconds); area under the time curve, AUC (in AU); slope of the wash-in curve, Pw (in AU per second); average transit time, MTT (in seconds). In addition, the personal, clinical and laboratory data necessary to determine the hepatological scores of disease severity such as MELD and Child-Pugh will be collected. The study has an expected duration of one year.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • written informed consent
  • adult patients (more than 18 years old)
  • focal liver lesions detectable with B-mode ultrasound

Exclusion

Exclusion Criteria:

  • liver failure,
  • hearth failure,
  • previous locoregional or systemic treatments for FLLs (e.g. ablation,chemoembolization, alcoholization, chemotherapy),
  • known allergy to ultrasound contrast agents
  • pregnancy
  • lactation

Study Design

Total Participants: 110
Treatment Group(s): 1
Primary Treatment: Ultrasound
Phase:
Study Start date:
March 13, 2020
Estimated Completion Date:
December 30, 2024

Connect with a study center

  • Fondazione Policlinico Gemelli IRCCS

    Roma, 00168
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.